Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The firm is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The firm's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The firm has operations in the United Kingdom and Belgium.
Follow-Up Questions
Who is the CEO of Genflow Biosciences PLC?
Dr. Eric Leire is the Chief Executive Officer of Genflow Biosciences PLC, joining the firm since 2021.
What is the price performance of GENFF stock?
The current price of GENFF is $0.0193, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Genflow Biosciences PLC?
Genflow Biosciences PLC belongs to Biotechnology industry and the sector is Health Care
What is Genflow Biosciences PLC market cap?
Genflow Biosciences PLC's current market cap is $8.7M
